The help wanted signs are up across the biopharma industry. According to BioSpace, companies are opening and expanding facilities, which is good news for job seekers.
Biogen reported that the company’s gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
Pfizer’s Covid-19 vaccine generates antibody responses three-and-a-half times larger in older people when a second dose is delayed to 12 weeks after the first, a British study said.
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
U.S. states are set to begin using the vaccine from Pfizer Inc. and BioNTech SE to inoculate young adolescents against Covid-19 after advisers to the U.S. Centers for Disease Control and Prevention (CDC) backed the plan in a unanimous vote on May 12.
Biogen Inc. exercised the company’s option to acquire TMS-007, an investigational drug for acute ischemic stroke, from TMS Co. Ltd.
Biogen and Capsigen forged a strategic collaboration to engineer novel adeno-associated virus (AAV) capsids that have the potential to become transformative gene therapies that treat underlying genetic causes of various central nervous system and neuromuscular disorders.
Building on the success of the company’s mRNA research, BioNTech will establish its first regional hub in the Asia Pacific region. The company will open a state-of-the-art manufacturing facility to support a global supply of mRNA-based vaccines and therapeutics in Singapore.
Novavax Inc. said on May 10 the company’s combined flu and Covid-19 vaccine produced functional antibodies against influenza and the coronavirus in a preclinical study.
Inovio Pharmaceuticals Inc. said the company’s Covid-19 vaccine candidate was safe, well-tolerated and produced immune response against the new coronavirus in a mid-stage clinical trial, sending the drug developer’s shares up over 3 percent.